If the biopharma industry wants to rely more on real-world data to support regulatory decision-making, it may need to look at endpoints different from those used in traditional clinical trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?